Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (43014)	4/23/2018 9:54:39 AM
From: Goose94	Respond to of 202400

Knight Therapeutics (GUD-T) tied it's three month high $8.10

To: Goose94 who wrote (43014)	6/1/2019 6:29:49 AM
From: Goose94	Read Replies (2) \| Respond to of 202400

Knight Therapeutics (GUD-T) revisited top pick from James Hodgins on BNN.ca Market Call Friday May 31st @ 1200ET Interestingly, Knight is trading now at just 1.3 times cash and roughly at its book value, which consists of cash and investments limiting the downside of the investment. There is no longer any premium built in forCEO Jonathan Goodman's expertise in the specialty pharma space. We believe that when the right transaction comes along as valuations fall,. Goodman will add significant value to shareholders.